Levodopa
Market by Application (Parkinson’s disease and Dopamine Responsive
Dystonia), by Drug Type (Rytary, Duopa, Sinemet, Canamet, and Others), by
Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies) and by Geography (North America, Europe, Asia Pacific, Latin
America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity
Analysis 2018 – 2026.
Levodopa or L-Dopa is a chemical
building-block that converts into a dopamine in body. Dopamine is the chemical
messenger released in brain. It mediates pleasure, cognition, and memory
functions. Nearly all patients receive the dopamine precursor levodopa, which
adequately control symptoms of Parkinson's disease (PD) at early stage of the
disease. Carbidopa is often included with levodopa-containing drugs in order to
boost its efficacy by slowing down the metabolism of dopamine.
Levodopa Market Driver
Development of novel formulations
and efficient drug delivery methods for levodopa are expected to drive growth
of the levodopa market. For instance, a clinical study for gastric retentive
Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is
ongoing in clinical phase III and is expected to complete in September 2018.
Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug
delivery system, which is designed to improve the efficacy and safety of
existing CD/LD drugs by utilizing an efficient gastric retention and specific
release mechanism.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2247
Moreover, Impel NeuroPharma Inc.
is conducting phase II clinical study for INP103, a drug-device combination
product containing a drug component, L-dopa, and device component I231
Precision Olfactory Delivery (POD) device. The study is expected to complete in
November 2018.
Furthermore, advancement in
diagnosis of Parkinson's disease (PD) progression is expected to boost growth
of levodopa market. For instance, a clinical study conducted by Washington
University School of Medicine, for measuring PD progression both by using
Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for
discovering suitable biomarker of PD is currently in clinical phase I and is
expected to complete in February 2019.
Levodopa Market Restraint
Shortage of drug supply in the
market due to delay in manufacturing and supply of levodopa is expected to
hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland
(Human Health) Ltd. in September 2018, anticipated stock shortage of some
Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due
to global manufacturing delays in production and demand for resupply of these
products.
Levodopa Market – Regional
Analysis
On the basis of region, the
global levodopa market is segmented into North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/levodopa-market-2247
North America is expected to
dominate the global levodopa market, owing to approval of new products by the U.S.
Food and Drug Administration (FDA). For instance, in 2015, FDA approved an
extended-release oral formulation of Levodopa/Carbidopa called Duopa,
manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation of
Carbidopa/Levodopa enteral suspension and is administered using a small,
portable infusion pump that delivers Carbidopa and Levodopa directly into the
small intestine, which continuously release over 16 hours in the body.
Europe region is expected to
witness significant growth in levodopa market due to involvement of key players
for marketing novel formulations in European region. For instance, Acorda
Therapeutics, Inc., in March 2018, submitted a Marketing Authorization
Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an
investigational inhaled levodopa treatment for symptoms of OFF periods (OFF
symptoms implies recurrence of symptoms such as rigidity, and tremors after
long period of levodopa use) in people with PD taking a Carbidopa/Levodopa
regimen.
Furthermore, in November 2015,
Impax Laboratories, Inc. received European Commission (EC) marketing
authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral
capsule formulation for the symptomatic treatment of adult patients with
Parkinson's disease in Europe region.
The key players operating in
levodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFang
Pharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical Industries
Ltd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2247
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment